PDL BioPharma — Q1 2017 Earnings Presentation
13 slides from PDL BioPharma's earnings presentation, May 3, 2017
Slide 1: First Quarter 2017 Financial Results Conference Call
PDL First Quarter 2017 Financial Results Conference Call May 3, 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actu
Slide 3: Focus: Long-term Value
Focus: Long-term Value o Focused on growth in order to continue value creation for shareholders. o Have committed over $1.4 billion and deployed over $1.1 billion since launching this strategy in 2012. o Expansion in our strategy with our first significant equity transaction with Noden Pharma DAC in
Slide 4: Noden Background
Noden Background o Noden Pharma = Domiciled in Ireland and has operating companies in US and EU. = Formed for the purpose of acquiring specialty pharma products. = PDL owns 98.8% of Noden and holds three of the five board seats. = Noden already has two products on the market—both indicated for hyper
Slide 5: Transitioning from Novartis Commercialization
Transitioning from Novartis Commercialization o US » Noden USA fielded a contract sales force of 40 dedicated solely to these products, in late February 2017. —Average tenure of US Noden sales force is ~12 years with over half having previous experience with hypertension products. « First quarter sa
Slide 6: Royalty & Debt Investments Current Deals
16 Royalty & Debt Investments 10 Current Deals Royalty Acquisition Royalty Acquisition ‘Senior Secured Royalty Acquisition Royalty Acquisition ‘Senior Secured Note 6 Concluded Deals Financing Purchase ‘| | AicelRx v k le [Pkybella| | <@SSERs) | can=anam aléo $2,500,000 $65,000,000 40,000,000 $89,600
Slide 7: Concluded ARIAD Transaction
Concluded ARIAD Transaction o Synthetic royalty transaction signed in July 2015. o PDL funded $100 million. o Acquisition of ARIAD by Takeda closed in February. o PDL exercised put option which resulted in repayment of 1.2x multiple of the $100 million, less royalty payments received by PDL thus far
Slide 8: Settlement of Merck Lawsuit
Settlement of Merck Lawsuit o Resolved patent infringement lawsuit with Merck related to manufacture and sale of product prior to the expiration of the Queen et al. patents in 2014 on favorable terms. o Announced settlement agreement in late April to resolve patent infringement lawsuit related to Me
Slide 9: Wellstat Diagnostics Foreclosure Process
Wellstat Diagnostics Foreclosure Process ONY State litigation to enforce the guarantee o In February of 2017, the Appellate Division of New York reversed a NY Supreme Court summary judgment decision which had been in PDL’s favor on strictly procedural grounds, but affirmed the denial by the NY Supre
Slide 10: First Quarter 2017 Financials
First Quarter 2017 Financials Three Months Ended Net income attributable to PDL's shareholders Net income per share - Basic Net income per share - Diluted March 31, (In thousands, except per share amounts) (unaudited) 2017 2016 Royalties from Queen et al. patents $14,156 _$ 121,455 Royalty rights -
Slide 11: First Quarter 2017 Financials
First Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) March 34, December 31, 2017 2016 Cash, cash equivalents and investments ‘!) $ 409,318 $ 242,141 Total notes receivable $ 261,025 $ 270,950 Total royalty rights - at fair value $ 293,801 $ 402,318 Total assets $ TASER 1,21
Slide 12: PDL Share Repurchase Program
PDL Share Repurchase Program o On March 1, 2017, PDL’s board authorized the repurchase of issued and outstanding PDL common stock having an aggregate value of up to $30 million through March 2018. o All shares repurchased will be retired and restored to authorized but unissued shares of common stock
Slide 13: Question and Answer Session
PDL Question and Answer Session